Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological Approach
暂无分享,去创建一个
[1] D. Lovinger,et al. Activation of NR2A-Containing NMDA Receptors Is Not Obligatory for NMDA Receptor-Dependent Long-Term Potentiation , 2005, The Journal of Neuroscience.
[2] V. Pawlak,et al. Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation , 2005, The Journal of Neuroscience.
[3] M. Zhuo,et al. Roles of NMDA receptor NR2A and NR2B subtypes for long‐term depression in the anterior cingulate cortex , 2005, The European journal of neuroscience.
[4] P. Paoletti,et al. Modulation of Triheteromeric NMDA Receptors by N-Terminal Domain Ligands , 2005, Neuron.
[5] P. Paoletti,et al. The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B , 2005, The Journal of Neuroscience.
[6] S. Cull-Candy,et al. Role of Distinct NMDA Receptor Subtypes at Central Synapses , 2004, Science's STKE.
[7] Alastair M. Hosie,et al. Zn2+ Ions: Modulators of Excitatory and Inhibitory Synaptic Activity , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[8] G. Collingridge,et al. Differential Roles of NR2A and NR2B-Containing NMDA Receptors in Cortical Long-Term Potentiation and Long-Term Depression , 2004, The Journal of Neuroscience.
[9] M. Sheng,et al. Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity , 2004, Science.
[10] H. Tse,et al. Structure–activity analysis of a novel NR2C/NR2D‐preferring NMDA receptor antagonist: 1‐(phenanthrene‐2‐carbonyl) piperazine‐2,3‐dicarboxylic acid , 2004, British journal of pharmacology.
[11] John R Huguenard,et al. Pathway-Specific Differences in Subunit Composition of Synaptic NMDA Receptors on Pyramidal Neurons in Neocortex , 2003, The Journal of Neuroscience.
[12] P. Paoletti,et al. Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors , 2002, The Journal of Neuroscience.
[13] Y. Auberson,et al. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. , 2002, Bioorganic & medicinal chemistry letters.
[14] Mark Farrant,et al. NMDA receptor subunits: diversity, development and disease , 2001, Current Opinion in Neurobiology.
[15] A. Fayyazuddin,et al. Molecular Organization of a Zinc Binding N-Terminal Modulatory Domain in a NMDA Receptor Subunit , 2000, Neuron.
[16] R. Dingledine,et al. The glutamate receptor ion channels. , 1999, Pharmacological reviews.
[17] R. Dingledine,et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition , 1998, Nature Neuroscience.
[18] S. Traynelis,et al. Control of Voltage-independent Zinc Inhibition of Nmda Receptors by the Nr1 Subunit , 2022 .
[19] P. Ascher,et al. High-Affinity Zinc Inhibition of NMDA NR1–NR2A Receptors , 1997, The Journal of Neuroscience.
[20] J. Kemp,et al. A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.
[21] J Kerby,et al. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. , 1995, Molecular pharmacology.
[22] M. Mishina,et al. Structure and function of the NMDA receptor channel , 1995, Neuropharmacology.
[23] D. Laurie,et al. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. , 1994, European journal of pharmacology.
[24] K Williams,et al. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. , 1993, Molecular pharmacology.
[25] Matthew T. Geballe,et al. Structure and Function of the NMDA Receptor , 2008 .